Because of challenges in performing routine personalized dosimetry in radiopharmaceutical
therapies, interest in single-time-point (STP) dosimetry, particularly using only a single …

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen
(PSMA) ligands have demonstrated promising results for the treatment of metastatic …

Purpose Accurate and precise renal dosimetry during 177Lu‐labeled prostate‐specific
membrane antigen (PSMA) radioligand therapy is crucial for therapy decisions. Sampling …

Background The number of SPECT/CT time-points is important for accurate patient dose
estimation in peptide receptor radionuclide therapy. However, it may be limited by the …

In this work, we present details and initial results from a 177 Lu dosimetry challenge that has
been designed to collect data from the global nuclear medicine community aiming at …

Purpose In recent years, targeted radionuclide therapy with [177 Lu-DOTA 0, Tyr 3]
octreotate for neuroendocrine tumours has yielded promising results. This therapy may be …

Objective. This study considers the error distributions for time-integrated activity (TIA) of
single-time-point (STP) methods for patient-specific dosimetry in radionuclide therapy …

Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally
resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative …

Background 177Lu-PSMA therapy has been successfully used to prolong the survival of
patients with metastatic castration-resistant prostate cancer. Patient-specific dosimetry …

In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias
(NENs), intratherapeutic dosimetry is mandatory for organs at risk (eg kidneys) and tumours …